# Australian PI – EPCLUSA® (sofosbuvir/velpatasvir)

# Name of the medicine

EPCLUSA (sofosbuvir/velpatasvir 400 mg/100 mg)tablets.

The active substances in EPCLUSA tablets are sofosbuvir and velpatasvir.

# Qualitative and quantitative composition

EPCLUSA is available as a fixed-dose combination tablet. Each tablet contains 100 mg velpatasvir and 400 mg sofosbuvir. EPCLUSA tablets are pink, diamond-shaped, film coated tablets, debossed with “GSI” on one side and “7916” on the other side.

For the full list of excipients, see Section 6.1 List of excipients.

# Pharmaceutical form

Each EPCLUSA tablet is film-coated and pink in colour. The tablets are diamond shaped debossed with “GSI” on one side and the number “7916” on the other side. The tablets are supplied in bottles with child-resistant closures.

# Clinical particulars

## Therapeutic indications

EPCLUSA is indicated for the treatment of chronic hepatitis C virus (HCV) infection (genotype 1, 2, 3, 4, 5 or 6) in adults and paediatric patients ≥ 12 years of age and weighing ≥ 30 kg.

(see 4.2 Dose and method of administration section for the recommended regimens for different patient subgroups).

## Dose and method of administration

The recommended dose of EPCLUSA in adults is one tablet, taken orally, once daily with or without food*.*

Table 1 provides the recommended treatment regimen based on adult patient population.

Table 1 Recommended Treatment Regimen Regardless of HCV Genotype

|  |  |
| --- | --- |
| **Adult Patient Population** | **Recommended Treatment Regimen** |
| Patients without cirrhosis and patients with compensated cirrhosis | EPCLUSA for 12 weeks |
| Patients with decompensated cirrhosis | EPCLUSA + ribavirina for 12 weeks |

1. In patients with decompensated cirrhosis, the ribavirin starting dose should be 600mg daily, with dose adjustment according to tolerance.

## Special Populations

## Paediatrics

In paediatric patients ≥ 12 years of age and weighing ≥ 30 kg, the recommended dosage of EPCLUSA is one tablet taken orally once daily with or without food for 12 weeks. EPCLUSA is not indicated for use in paediatric patients < 12 years of age or weighing < 30 kg.

**Elderly**

No dose adjustment is warranted for elderly patients.

**Renal Impairment**

No dose adjustment of EPCLUSA is required for patients with renal impairment, including end stage renal disease (ESRD) requiring dialysis (see 5.2 Pharmacokinetic properties: Special Populations). Safety data are limited in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) and ESRD who are not receiving haemodialysis.

**Hepatic Impairment**

No dose adjustment of EPCLUSA is required for patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C) (see 5.2 Pharmacokinetic properties: Special Populations). Safety and efficacy of EPCLUSA have been established in adult patients with decompensated cirrhosis (see 4.8 Adverse Effects (Undesirable effects) and 5.1 Pharmacodynamic properties, Clinical Trials).

## Contraindications

EPCLUSA tablets are contraindicated in patients with known hypersensitivity to the active substance or to any other component of the tablets.

EPCLUSA is a fixed-dose combination of sofosbuvir and velpatasvir. EPCLUSA should not be administered concurrently with other medicinal products containing any of the same active components.

## Special warnings and precautions for use

### Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone

Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with a sofosbuvir-containing regimen. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir-containing regimen (ledipasvir/sofosbuvir).

Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for this effect is unknown.

Coadministration of amiodarone with EPCLUSA is not recommended. For patients taking amiodarone who have no other alternative, viable treatment options and who will be coadministered EPCLUSA:

* Counsel patients about the risk of symptomatic bradycardia
* Cardiac monitoring in an in-patient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.

Patients who are taking EPCLUSA who need to start amiodarone therapy due to no other alternative, viable treatment options should undergo similar cardiac monitoring as outlined above.

Due to amiodarone’s long half-life, patients discontinuing amiodarone just prior to starting EPCLUSA should also undergo similar cardiac monitoring as outlined above.

Patients who develop signs or symptoms of bradycardia should seek medical evaluation immediately. Symptoms may include near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion, or memory problems.

**Hepatitis B Virus Reactivation**

Cases of Hepatitis B virus (HBV) reactivation, including fatal cases, have been reported during and after treatment of HCV with direct-acting antiviral agents in HCV/HBV co-infected patients. Screening for current or past HBV infection, including testing for HBV surface antigen (HBsAg) and HBV core antibody (anti-HBc), should be performed in all patients before initiation of treatment with EPCLUSA.

Patients with serologic evidence of current or past HBV infection should be monitored and treated according to current clinical practice guidelines to manage potential HBV reactivation. Consider initiation of HBV antiviral therapy, if indicated.

**Use with Moderate Inducers of P-gp and/or Moderate to Strong Inducers of CYP**

Drugs that are moderate inducers of P-gp and/or moderate to strong inducers of CYP2B6, CYP2C8, or CYP3A4 (e.g., rifampin, St. John’s wort, carbamazepine) may significantly decrease plasma concentrations of sofosbuvir and/or velpatasvir leading to reduced therapeutic effect of EPCLUSA. The use of these agents with EPCLUSA is not recommended (see 4.5 Interactions with other medicines and other forms of interactions).

### Use in the elderly

Clinical studies of EPCLUSA included 156 patients aged 65 and over (12% of total number of patients in the Phase 3 clinical trials). No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

### Paediatric use

The safety and efficacy of EPCLUSA in paediatric patients ≥ 12 years of age receiving EPCLUSA once daily have been established [see 4.8 Adverse effects (Undesirable effects) and 5.1 Pharmacodynamic properties: Clinical Trials]. Exposures to EPCLUSA in paediatric patients ≥ 12 to < 18 years of age and weighing ≥ 30 kg were similar to those observed in adults.

**Effects on laboratory tests**

As liver function may change during treatment with EPCLUSA, please see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions, Other Forms of Interaction for additional guidance on monitoring of certain laboratory parameters and/or concomitant medications.

## Interactions with other medicines and other forms of interactions

As EPCLUSA contains sofosbuvir and velpatasvir, any interactions that have been identified with these agents individually may occur with EPCLUSA.

### Potential for EPCLUSA to Affect Other Drugs

Velpatasvir is an inhibitor of drug transporter P-gp, BCRP, OATP1B1 and OATP1B3. Coadministration of EPCLUSA with drugs that are substrates of these transporters may increase the exposure of such drugs. The drug-drug interaction potential of velpatasvir is limited to the presystemic processes (intestinal efflux and hepatic uptake); clinically relevant interactions in systemic circulation are not expected.

### Potential for Other Drugs to Affect EPCLUSA

Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP while GS-331007 is not. *In vitro*, slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed.

Drugs that are moderate inducers of P-gp and/or moderate to strong inducers of CYP2B6, CYP2C8, or CYP3A4 (e.g., rifampin, St. John’s wort, carbamazepine) may decrease plasma concentrations of sofosbuvir and/or velpatasvir leading to reduced therapeutic effect of EPCLUSA. The use of these agents with EPCLUSA is not recommended (see 4.4 Special warnings and precautions for use: Use with Moderate Inducers of P-gp and/or Moderate to Strong Inducers of CYP). Coadministration with drugs that inhibit P-gp and/or BCRP may increase sofosbuvir and/or velpatasvir plasma concentrations without increasing GS-331007 plasma concentration. Drugs that inhibit CYP2B6, CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. EPCLUSA may be coadministered with P-gp, BCRP, and CYP inhibitors.

### Established and Other Potentially Significant Drug Interactions

Table 2 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either EPCLUSA, the components of EPCLUSA (sofosbuvir and velpatasvir) as individual agents, or are predicted drug interactions that may occur with EPCLUSA. This table is not all inclusive (see 5.2 Pharmacokinetic properties, Assessment of Drug Interactions).

**Table 2 Established and Other Potentially Significanta Drug Interactions**

| **Concomitant Drug Class: Drug Name** | **Effect on Concentrationb** | **Clinical Comment** |
| --- | --- | --- |
| **Acid Reducing Agents:** | ↓ velpatasvir | Velpatasvir solubility decreases as pH increases. Drugs that increase gastric pH are expected to decrease concentration of velpatasvir. |
| Antacids (e.g., aluminum and magnesium hydroxide) |  | It is recommended to separate antacid and EPCLUSA administration by 4 hours. |
| H2-receptor antagonists (e.g., famotidine)c |  | H2-receptor antagonists may be administered simultaneously with or staggered from EPCLUSA at a dose that does not exceed doses comparable with famotidine 40 mg twice daily. |
| Proton-pump inhibitors (e.g., omeprazole)c |  | Proton-pump inhibitor doses comparable with omeprazole 20 mg can be administered with EPCLUSA when EPCLUSA is administered with food. |
| **Antiarrhythmics:**  amiodarone | Effect on amiodarone, sofosbuvir, and velpatasvir concentrations unknown | Coadministration of amiodarone with EPCLUSA may result in symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with EPCLUSA is not recommended; if coadministration is required, cardiac monitoring is recommended (see *Precautions: Serious Symptomatic Bradycardia When Coadministered with Amiodarone*). |
| digoxinc | ↑ digoxin | Coadministration of EPCLUSA with digoxin may increase the concentration of digoxin. Caution is warranted and therapeutic concentration monitoring of digoxin is recommended when coadministered with EPCLUSA. |
| **Anticonvulsants:**  carbamazepinec  phenytoin  phenobarbital | ↓ sofosbuvir  ↓ velpatasvir | Coadministration of EPCLUSA with carbamazepine, phenytoin or phenobarbital is expected to decrease the concentration of sofosbuvir and/or velpatasvir, leading to reduced therapeutic effect of EPCLUSA. Coadministration is not recommended. |
| **Antimycobacterials:**  rifabutinc rifampinc rifapentine | ↓ sofosbuvir  ↓ velpatasvir | Coadministration of EPCLUSA with rifabutin, rifampin, or rifapentine is expected to decrease the concentration of sofosbuvir and/or velpatasvir, leading to reduced therapeutic effect of EPCLUSA. Coadministration is not recommended. |
| **Antiretrovirals:**  efavirenzc | ↓ velpatasvir | Coadministration of EPCLUSA with efavirenz is expected to decrease the concentration of velpatasvir.  Coadministration of EPCLUSA with efavirenz containing regimens is not recommended. |
| tenofovir disoproxil fumarate (tenofovir DF)c | ↑ tenofovir | EPCLUSA has been shown to increase tenofovir exposure. Patients receiving tenofovir DF and EPCLUSA concomitantly should be monitored for adverse reactions associated with tenofovir DF. Refer to the tenofovir DF-containing product’s product information for recommendations on renal monitoring. |
| **Herbal Supplements:**  St. John’s wort | ↓ sofosbuvir  ↓ velpatasvir | Coadministration of EPCLUSA with St. John’s wort is expected to decrease the concentration of sofosbuvir and velpatasvir, leading to reduced therapeutic effect of EPCLUSA. Coadministration is not recommended. |
| **HMG-CoA Reductase Inhibitors:**  rosuvastatinc | ↑ rosuvastatin | Coadministration of EPCLUSA with rosuvastatin may increase the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis. Rosuvastatin may be administered with EPCLUSA at a dose that does not exceed 10 mg. |

a This table is not all inclusive.

b ↑ = increase, ↓ = decrease, ↔ = no effect

c These interactions have been studied in healthy adults.

**Drugs without Clinically Significant Interactions with EPCLUSA**

Based on drug interaction studies conducted with the components of EPCLUSA (sofosbuvir or velpatasvir) or EPCLUSA, no clinically significant drug interactions have either been observed or are expected when EPCLUSA is combined with the following drugs (see 5.2 Pharmacokinetic properties, Assessment of Drug Interactions): atazanavir/ritonavir, atorvastatin, cyclosporine, darunavir/ritonavir, dolutegravir, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, ketoconazole, lopinavir/ritonavir, methadone, oral contraceptives, oxcarbazepine, pravastatin, raltegravir, rilpivirine, or tacrolimus (see 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction: Other Forms of Interaction).

**Other Forms of Interaction**

Change in hepatic function as a result of treatment of HCV with DAAs may require monitoring of relevant laboratory parameters in susceptible patients (e.g., International Normalized Ratio [INR] in patients taking vitamin K antagonists, blood glucose levels in diabetic patients). Concomitant medications significantly affected by changes in hepatic function (e.g., calcineurin inhibitors) may require monitoring or dose modification to ensure continued efficacy.

## Fertility, pregnancy and lactation

### Effects on Fertility

*Sofosbuvir*: Sofosbuvir had no effects on embryo-fetal viability or on fertility when evaluated in rats. At the highest dose tested, AUC exposure to the predominant circulating metabolite GS-331007 was approximately 4-fold the exposure in humans at the recommended clinical dose.

*Velpatasvir*: Velpatasvir had no effects on embryo-fetal viability or on fertility when evaluated in rats. At the highest dose tested, velpatasvir exposure was approximately 6-fold the exposure in humans at the recommended clinical dose.

### Use in Pregnancy

EPCLUSA (Pregnancy Category B1)

There are no adequate and well-controlled studies with EPCLUSA in pregnant women.

In animal reproduction studies, no evidence of adverse developmental outcomes was observed with the administration of sofosbuvir or velpatasvir.

*Sofosbuvir*: No effect on fetal development has been observed in rats and rabbits at the highest doses tested. In the rat and rabbit, exposure to the predominant circulating metabolite GS-331007 was approximately 2- to 5-fold and 6- to 14-fold the exposure in humans at the recommended clinical dose, respectively. Sofosbuvir had no adverse effects on behaviour, reproduction, or development of the offspring in the rat pre- and post-natal development study at AUC exposures approximately 6-fold higher than the human exposure at the recommended clinical dose.

*Velpatasvir*: No effects on fetal development have been observed in mice, rats and rabbits at the highest doses tested. In the mouse, rat and rabbit, AUC exposure to velpatasvir was approximately 31-, 6-, and 0.7-fold, respectively, the exposure in humans at the recommended clinical dose. Velpatasvir had no adverse effects on behaviour, reproduction, or development of the offspring in the rat pre- and post-natal development study at AUC exposures approximately 5-fold higher, respectively than the human exposure at the recommended clinical dose.

Because animal reproduction studies are not always predictive of human response, EPCLUSA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Ribavirin (Pregnancy Category X)

Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. When EPCLUSA is used in combination with ribavirin extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Women of childbearing potential and their male partners must use effective contraception during treatment and for approximately six months after the treatment has concluded as recommended in the product information for ribavirin. If ribavirin is co-administered with EPCLUSA, the contraindications regarding use of ribavirin apply (refer to ribavirin product information).

### Use in Lactation.

It is not known whether sofosbuvir or velpatasvir or their metabolites are present in human breast milk.

The predominant circulating metabolite of sofosbuvir (GS-331007) was the primary component observed in the milk of lactating rats, without effect on nursing pups. Velpatasvir was present in the milk of lactating rats, without clear effects on nursing pups. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for EPCLUSA and any potential adverse effects on the breastfed infant from EPCLUSA or from the underlying maternal condition.

## Effects on ability to drive and use machines

No studies on the effects of EPCLUSA on the ability to drive and use machines have been performed.

## Adverse effects (Undesirable effects)

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at https://www.tga.gov.au/reporting-problems.

### Adults

### Clinical Trials

The safety assessment of EPCLUSA is based on pooled Phase 3 clinical trial data (ASTRAL-1, ASTRAL-2, and ASTRAL-3) from patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection (with or without compensated cirrhosis) including:

* 1035 patients who received EPCLUSA for 12 weeks,
* 116 patients who received placebo (PBO) for 12 weeks,
* 132 patients who received sofosbuvir (SOF) + ribavirin (RBV) for 12 weeks,
* 275 patients who received SOF + RBV for 24 weeks

The proportion of patients who permanently discontinued treatment due to adverse events was 0.2% for patients receiving EPCLUSA for 12 weeks.

No adverse drug reactions specific to EPCLUSA have been identified. In clinical trials, headache, fatigue, nausea, and nasopharyngitis were the most common (incidence ≥10%) treatment emergent adverse events reported in patients treated with 12 weeks of EPCLUSA.

Table 3 lists adverse events observed in at least 5% of patients receiving 12 weeks treatment with EPCLUSA in clinical trials compared to placebo. The majority of adverse events presented in Table 3 occurred at severity of grade 1.

Table 3 Adverse Events (All Grades and without Regard to Causality) Reported in ≥5% of Patients Receiving 12 Weeks of Treatment with EPCLUSA Compared to Placebo

|  |  |  |
| --- | --- | --- |
|  | **EPCLUSA 12 weeks (N=1035)** | **Placebo 12 weeks (N=116)** |
| Headache | 29% | 28% |
| Fatigue | 21% | 20% |
| Nausea | 13% | 11% |
| Nasopharyngitis | 12% | 10% |
| Insomnia | 8% | 9% |
| Diarrhea | 7% | 7% |
| Asthenia | 6% | 8% |
| Cough | 6% | 3% |
| Back pain | 5% | 9% |
| Arthralgia | 5% | 8% |

### Patients with Decompensated Cirrhosis

No adverse drug reactions specific to EPCLUSA were identified from one open-label trial (ASTRAL-4) in which patients with Child-Pugh Class B cirrhosis received EPCLUSA for 12 weeks (N=90), EPCLUSA+RBV for 12 weeks (N=87) or EPCLUSA for 24 weeks (N=90). The adverse events observed were consistent with expected clinical sequelae of decompensated liver disease, or the known toxicity profile of ribavirin for patients receiving EPCLUSA in combination with RBV.

Among the 87 patients who were treated with EPCLUSA+RBV for 12 weeks, decreases in haemoglobin to less than 10 mg/dL and 8.5 mg/dL during treatment were experienced by 23% and 7% patients, respectively. Ribavirin was discontinued in 15% of patients treated with EPCLUSA+RBV for 12 weeks due to adverse events.

**HCV/HIV-1 Co-infection**

No adverse drug reactions specific to EPCLUSA were identified from a Phase 3 open-label clinical trial (ASTRAL-5) in which patients with HCV/HIV-1 co-infection received treatment with EPCLUSA for 12 weeks (N=106)

**Patients with Renal Impairment**

No adverse reactions specific to EPCLUSA were identified from an open-label clinical trial (GS-US-342-4062) in which a total of 59 patients with HCV and ESRD requiring dialysis received EPCLUSA for 12 weeks. The adverse events observed were consistent with expected clinical sequelae of ESRD.

**Paediatrics**

The safety of EPCLUSA in paediatric patients ≥ 12 years of age was assessed in an open-label trial (Study GS-US-342-1143, Cohort 1) of 102 patients who were treated with EPCLUSA for 12 weeks. The adverse reactions observed were consistent with those observed in clinical trials of EPCLUSA in adults (see 5.1 Pharmacodynamic properties, Clinical Trials).

### Post marketing Surveillance

The following possible adverse reactions were identified during postapproval use of sofosbuvir or EPCLUSA. Because these reactions were reported voluntarily from a population of unknown size, estimates of frequency cannot be made.

### Cardiac Disorders

Symptomatic bradycardia (when amiodarone is coadministered with EPCLUSA) (see 4.4 Special warning and precautions for use: Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone ).

Skin and Subcutaneous Tissue Disorders

Angioedema, rash

## Overdose

The highest documented doses of sofosbuvir and velpatasvir were a single dose of 1200 mg and a single dose of 500 mg, respectively. In these healthy volunteer studies, there were no untoward effects observed at these dose levels, and adverse events were similar in frequency and severity to those reported in the placebo groups. The effects of higher doses/exposures are not known.

No specific antidote is available for overdose with EPCLUSA. If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose with EPCLUSA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Haemodialysis can efficiently remove the predominant circulating metabolite of sofosbuvir, GS-331007, with an extraction ratio of 53%. Haemodialysis is unlikely to result in significant removal of velpatasvir since velpatasvir is highly bound to plasma protein.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia) and 0800 764 766 (New Zealand).

# Pharmacological properties

## Pharmacodynamic properties

Pharmacotherapeutic group: Antivirals for systemic use; direct acting antivirals, other antivirals, ATC code: J05AX69

### Mechanism of action

Sofosbuvir is a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated by HCV NS5B and acts as a chain terminator. In a biochemical assay, GS-461203 inhibited the polymerase activity of the recombinant NS5B from HCV genotype 1b, 2a, 3a and 4a with an IC50 value ranging from 0.36 to 3.3 μM. GS-461203 is neither an inhibitor of human DNA and RNA polymerases nor an inhibitor of mitochondrial RNA polymerase.

Velpatasvir is a HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA replication and the assembly of HCV virions. *In vitro* resistance selection and cross-resistance studies indicate velpatasvir targets NS5A as its mode of action.

**Antiviral activity *in vitro***

The EC50 values of sofosbuvir and velpatasvir against full-length or chimeric replicons encoding NS5B and NS5A sequences from the laboratory strains are presented in Table 4. The EC50values of sofosbuvir and velpatasvir against chimeric replicons representing clinical isolates are presented in Table 5.

**Table 4 Activity of Sofosbuvir and Velpatasvir Against Full Length or Chimeric Laboratory Replicons**

|  |  |  |
| --- | --- | --- |
| **Replicon Genotype** | **Sofosbuvir EC50, nMa** | **Velpatasvir EC50, nMa** |
| 1a | 40 | 0.014 |
| 1b | 110 | 0.016 |
| 2a | 50 | 0.005-0.016c |
| 2b | 15b | 0.002-0.006c |
| 3a | 50 | 0.004 |
| 4a | 40 | 0.009 |
| 4d | NA | 0.004 |
| 5a | 15b | 0.021-0.054d |
| 6a | 14b | 0.006-0.009 |
| 6e | NA | 0.130d |
| NA=Not Available  a. Mean value from multiple experiments of same laboratory replicon.  b. Stable chimeric 1b replicons carrying NS5B genes from genotype 2b, 5a, or 6a were used for testing.  c. Data from various strains of full length NS5A replicons or chimeric NS5A replicons carrying full-length NS5A genes that contain L31 or M31 polymorphisms.  d. Data from a chimeric NS5A replicon carrying NS5A amino acids 9-184. | | |

**Table 5 Activity of Sofosbuvir and Velpatasvir Against Transient Replicons   
 Containing NS5A or NS5B from Clinical Isolates**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Replicon Genotype** | **Replicons containing NS5B from clinical isolates** | | **Replicons containing NS5A from  clinical isolates** | |
| **Number of  clinical isolates** | **Median sofosbuvir**  **EC50, nM (range)** | **Number of  clinical isolates** | **Median velpatasvir EC50, nM (range)** |
| 1a | 67 | 62 (29-128) | 23 | 0.019 (0.011-0.078) |
| 1b | 29 | 102 (45-170) | 34 | 0.012 (0.005-0.500) |
| 2a | 15 | 29 (14-81) | 8 | 0.011 (0.006-0.364) |
| 2b | NA | NA | 16 | 0.002 (0.0003-0.007) |
| 3a | 106 | 81 (24-181) | 38 | 0.005 (0.002-1.871) |
| 4a | NA | NA | 5 | 0.002 (0.001-0.004) |
| 4d | NA | NA | 10 | 0.007 (0.004-0.011) |
| 4r | NA | NA | 7 | 0.003 (0.002-0.006) |
| 5a | NA | NA | 42 | 0.005 (0.001-0.019) |
| 6a | NA | NA | 26 | 0.007 (0.0005-0.113) |
| 6e | NA | NA | 15 | 0.024 (0.005-0.433) |

NA=Not Available

The presence of 40% human serum had no effect on the anti-HCV activity of sofosbuvir, but reduced the anti-HCV activity of velpatasvir by 13-fold against genotype 1a HCV replicons.

Evaluation of sofosbuvir in combination with velpatasvir showed no antagonistic effect in reducing HCV RNA levels in replicon cells.

**Drug Resistance**

In Cell Culture:

HCV replicons with reduced susceptibility to sofosbuvir have been selected in cell culture for multiple genotypes including 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Reduced susceptibility to sofosbuvir was associated with the primary NS5B substitution S282T in all replicon genotypes examined. Site-directed mutagenesis of the S282T substitution in replicons of genotype 1 to 6 conferred 2- to 18-fold reduced susceptibility to sofosbuvir and reduced the replication viral capacity by 89% to 99% compared to the corresponding wild-type. In biochemical assays, the ability of the active triphosphate of sofosbuvir (GS-461203) to inhibit recombinant NS5B polymerase from genotypes 1b, 2a, 3a, and 4a expressing the S282T substitution was reduced compared to its ability to inhibit wild-type recombinant NS5B polymerase, as indicated by a 8.5- to 24-fold increase in IC50.

*In vitro* selection of HCV replicons with reduced susceptibility to velpatasvir was performed in cell culture for multiple genotypes including 1a, 1b, 2a, 3a, 4a, 5a, and 6a. Variants were selected at NS5A resistance associated positions 24, 28, 30, 31, 32, 58, 92, and 93. The resistance associated variants (RAVs) selected in 2 or more genotypes were F28S, L31I/V, and Y93H. Site-directed mutagenesis of known NS5A RAVs showed that substitutions conferring a >100-fold reduction in velpatasvir susceptibility are M28G, A92K, and Y93H/N/R/W in genotype 1a, A92K in genotype 1b, C92T and Y93H/N in genotype 2b, Y93H in genotype 3, and L31V and P32A/L/Q/R in genotype 6. No individual substitutions tested in genotypes 2a, 4a, or 5a conferred a >100 fold reduction in velpatasvir susceptibility. Combinations of these variants often showed greater reductions in susceptibility to velpatasvir than single RAVs alone.

In Clinical Trials

*Studies in Patients without Cirrhosis and Patients with Compensated Cirrhosis*

In a pooled analysis of patients without cirrhosis or with compensated cirrhosis who received EPCLUSA for 12 weeks in Phase 3 trials (ASTRAL-1, ASTRAL-2, and ASTRAL-3), 12 patients (2 with genotype 1 and 10 with genotype 3) qualified for resistance analysis due to virologic failure. One additional patient with genotype 3 HCV infection at baseline was reinfected with genotype 1a HCV at virologic failure and was excluded from the virological analysis. No patients with genotype 2, 4, 5, or 6 HCV infection experienced virologic failure.

Of the 2 genotype 1 virologic failure patients, 1 patient had virus with emergent NS5A RAV Y93N and the other patient had virus with emergent NS5A RAVs L31I/V and Y93H at virologic failure. Both patients had virus at baseline harboring NS5A RAVs. No NS5B nucleoside inhibitor (NI) RAVs were observed at failure in the two patients.

Of the 10 genotype 3 virologic failure patients, Y93H was observed in all 10 patients at failure (6 had Y93H emerge post-treatment and 4 patients had Y93H at baseline and post-treatment). No NS5B NI RAVs were observed at failure in the 10 patients.

*Studies in Patients with Decompensated Cirrhosis*

In the ASTRAL-4 trial, in patients with decompensated cirrhosis who received EPCLUSA + ribavirin (RBV) for 12 weeks, 3 patients (1 with genotype 1 and 2 with genotype 3) qualified for resistance analysis due to virologic failure. No patients with genotype 2 or 4 HCV infection in the EPCLUSA + RBV 12 Weeks group experienced virologic failure.

The 1 virologic failure patient with genotype 1 HCV had no NS5A or NS5B RAVs at failure.

Of the 2 genotype 3 virologic failure patients, one had NS5A RAV Y93H emerge at failure. Another patient had virus with Y93H at baseline and virologic failure and also developed low levels (<5%) of NS5B NI RAVs N142T and E237G at failure. Pharmacokinetic data from this patient was consistent with non-adherence.

In the ASTRAL-4 trial, 2 patients treated with EPCLUSA for 12 or 24 weeks without ribavirin had emergent NS5B S282T at low levels (<5%) along with L159F.

**Effect of Baseline HCV Resistance Associated Variants on Treatment Outcome**

**Adults**

*Studies in Patients without Cirrhosis and Patients with Compensated Cirrhosis*

Analyses were conducted to explore the association between pre-existing baseline NS5A RAVs and treatment outcome for patients without cirrhosis or with compensated cirrhosis (ASTRAL-1, ASTRAL-2, and ASTRAL-3). Of the 1035 patients treated with EPCLUSA in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 trials, 1023 patients were included in the analysis of NS5A RAVs; 7 patients were excluded as they neither achieved sustained virologic response (SVR12) nor had virologic failure and 5 additional patients were excluded as NS5A gene sequencing failed. In the pooled analysis of the Phase 3 trials, 380/1023 (37%) patients’ virus had baseline NS5A RAVs. Genotype 2, 4, and 6 HCV infected patients had a higher prevalence of NS5A RAVs (70%, 63%, and 52%, respectively) compared to genotype 1 (23%), genotype 3 (16%), and genotype 5 (18%) HCV infected patients.

SVR12 in patients with or without baseline NS5A RAVs in ASTRAL-1, ASTRAL-2, and ASTRAL-3 trials is shown in Table 6.

**Table 6 Studies ASTRAL-1, ASTRAL-2, and ASTRAL-3: SVR12 in Patients With or Without Baseline NS5A RAVs by HCV Genotype**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **EPCLUSA 12 Weeks** | | | |
| **Genotype 1** | **Genotype 3** | **Genotype 2, 4, 5 or 6** | **Total** |
| With any baseline  NS5A RAVs | 97% (73/75) | 88% (38/43) | 100% (262/262) | 98% (373/380) |
| Without baseline  NS5A RAVs | 100% (251/251) | 97% (225/231) | 100% (161/161) | 99% (637/643) |

Among the 75 genotype 1 patients who had baseline NS5A RAVs, SVR12 was 97% (67/69) and 100% (6/6) in patients with baseline NS5A RAVs that confer ≤100-fold and >100-fold reduced susceptibility to velpatasvir, respectively. Among the 43 genotype 3 patients who had baseline NS5A RAVs, SVR12 was 94% (15/16) and 85% (23/27) in patients with NS5A RAVS that confer ≤100-fold and >100-fold reduced susceptibility to velpatasvir, respectively. The 4 genotype 3 patients who had baseline NS5A RAVs conferring >100-fold reduced susceptibility to velpatasvir and failed to achieve SVR12, all had NS5A substitution Y93H at baseline. Twenty-one of 25 (84%) genotype 3 patients with baseline NS5A substitution Y93H achieved SVR12.

The NS5B NI RAV S282T was not detected in the baseline NS5B sequence of any patient in Phase 3 trials. SVR12 was achieved in all 77 patients who had baseline NS5B NI RAVs including N142T, L159F, E/N237G, C/M289L/I, L320F/I/V, V321A/I, and S282G+V321I.

*Studies in Patients**with Decompensated Cirrhosis*

Analyses were conducted to explore the association between pre-existing baseline NS5A RAVs and treatment outcome for patientswith decompensated cirrhosis (ASTRAL-4). Of the 87 patientstreated with EPCLUSA + RBV in the ASTRAL-4 trial, 85 patientswere included in the analysis of NS5A RAVs; 2 patientswere excluded as they neither achieved SVR12 nor had virologic failure. Among the patientswho received treatment with EPCLUSA + RBV for 12 weeks, 29% (25/85) of patientshad baseline virus with NS5A RAVs [29% (19/66), 75% (3/4), 15% (2/13), and 50% (1/2) for patients with genotype 1, 2, 3, and 4 HCV, respectively].

SVR12 in patients with or without baseline NS5A RAVs in the EPCLUSA + RBV 12 week group of ASTRAL-4 trial is shown in Table 7.

**Table 7 Study ASTRAL-4: SVR12 in Patients With or Without Baseline NS5A RAVs by HCV Genotype**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **EPCLUSA + RBV 12 Weeks** | | | |
| **Genotype 1** | **Genotype 3** | **Genotype 2 or 4** | **Total** |
| With any baseline NS5A RAVs | 100% (19/19) | 50% (1/2) | 100% (4/4) | 96% (24/25) |
| Without baseline  NS5A RAVs | 98% (46/47) | 91% (10/11) | 100% (2/2) | 98% (58/60) |

The single genotype 3 patient who had baseline NS5A RAVs and failed to achieve SVR12 had NS5A substitution Y93H at baseline; pharmacokinetic data from this patient was consistent with non-adherence.

Three patients in the EPCLUSA + RBV 12 week group had baseline NS5B NI RAVs (N142T and L159F) and all three patients achieved SVR12.

**Paediatrics**

In Study GS-US-342-1143, the presence of NS5A and NS5B RAVs did not impact treatment outcome; all paediatric patients 12 years to < 18 years of age with baseline NS5A or NS5B NI RAVs (16.3% [16/98] and 5.2% [5/97], respectively) achieved SVR following 12 weeks treatment with EPCLUSA.

**Cross Resistance**

*In vitro* data suggest that the majority of NS5A RAVs that confer resistance to ledipasvir and daclatasvir remained susceptible to velpatasvir. Velpatasvir was fully active against the sofosbuvir resistance-associated substitution S282T in NS5B, while all velpatasvir resistance-associated substitutions in NS5A were fully susceptible to sofosbuvir. Both sofosbuvir and velpatasvir were fully active against substitutions associated with resistance to other classes of direct acting antivirals with different mechanisms of actions, such as NS5B non-nucleoside inhibitors and NS3 protease inhibitors. The efficacy of EPCLUSA has not been established in patients who have previously failed treatment with other regimens that include an NS5A inhibitor.

**CLINICAL TRIALS**

**Adults**

**Description of Clinical Studies**

The efficacy of EPCLUSA was evaluated in three Phase 3 trials in patients with genotype 1 to 6 HCV infection with or without compensated cirrhosis and one Phase 3 trial in patients with genotype 1 to 6 HCV infection with decompensated cirrhosis, one Phase 3 study in HCV/HIV-1 co-infected patients with genotype 1 to 6 HCV infection and one Phase 2 trial in patients with HCV infection and ESRD requiring dialysis, as summarised in Table 8.

**Table 8 Trials Conducted with EPCLUSA in Patients with Genotype 1, 2, 3, 4, 5 or 6 HCV Infection**

|  |  |  |
| --- | --- | --- |
| **Trial** | **Population** | **Study Arms (Number of Patients Treated)** |
| ASTRAL-1 | Genotype 1, 2, 4, 5, and 6 TN and TE, without cirrhosis or with compensated cirrhosis | EPCLUSA 12 weeks (624)  Placebo 12 weeks (116) |
| ASTRAL-2 | Genotype 2  TN and TE, without cirrhosis or with compensated cirrhosis | EPCLUSA 12 weeks (134)  SOF+RBV 12 weeks (132) |
| ASTRAL-3 | Genotype 3 TN and TE, without cirrhosis or with compensated cirrhosis | EPCLUSA 12 weeks (277)  SOF+RBV 24 weeks (275) |
| ASTRAL-4 | Genotype 1, 2, 3,4, 5, and 6  TN and TE, with CPT class B decompensated cirrhosis | EPCLUSA 12 weeks (90) EPCLUSA+RBV 12 weeks (87)  EPCLUSA 24 weeks (90) |
| ASTRAL‑5 | Genotype 1, 2, 3, 4, 5 and 6  TN and TE, without cirrhosis or with compensated cirrhosis, with HCV/HIV-1 co-infection | EPCLUSA 12 weeks (106) |
| Study  GS-US-342-4062 | Genotype 1,2,3,4,5 and 6 TN and TE without cirrhosis or without compensated cirrhosis, with ESRD | EPCLUSA 12 weeks (59) |

TN: treatment-naïve patients;

TE: treatment-experienced patients (including those who have failed a peginterferon alfa + ribavirin based regimen with or without an HCV protease inhibitor);

SOF=sofosbuvir,

RBV=ribavirin,

CPT=Child Pugh Turcotte

ESRD: End Stage Renal Disease

The ribavirin dose was weight-based (1000 mg daily administered in two divided doses for patients < 75 kg and 1200 mg for those ≥ 75 kg) and administered in two divided doses when used in combination with sofosbuvir in the ASTRAL-2 and ASTRAL-3 trials or in combination with EPCLUSA in the ASTRAL-4 trial. RBV dose adjustments were performed according to the RBV product information. Serum HCV RNA values were measured during the clinical trials using the COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with a lower limit of quantification (LLOQ) of 15 IU per mL. Sustained virologic response (SVR12), defined as HCV RNA less than LLOQ at 12 weeks after the cessation of treatment, was the primary endpoint to determine the HCV cure rate.

**Clinical Studies in Patients without Cirrhosis and Patients with Compensated Cirrhosis**

Genotype 1, 2, 4, 5, and 6 HCV-Infected Adults (ASTRAL-1)

ASTRAL-1 was a randomised, double-blind, placebo-controlled trial that evaluated 12 weeks of treatment with EPCLUSA compared with 12 weeks of placebo in patients with genotype 1, 2, 4, 5, or 6 HCV infection. Patients with genotype 1, 2, 4, or 6 HCV infection were randomised in a 5:1 ratio to treatment with EPCLUSA for 12 weeks or placebo for 12 weeks. Patients with genotype 5 HCV infection were enrolled to the EPCLUSA group. Randomisation was stratified by HCV genotype (1, 2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.

Demographics and baseline characteristics were balanced between the EPCLUSA and placebo group. Of the 740 treated patients, the median age was 56 years (range: 18 to 82); 60% of the patients were male; 79% were White, 9% were Black; 21% had a baseline body mass index at least 30 kg/m2; the proportions of patients with genotype 1, 2, 4, 5, or 6 HCV infection were 53%, 17%, 19%, 5%, and 7%, respectively; 69% had non-CC IL28B alleles (CT or TT); 74% had baseline HCV RNA levels at least 800,000 IU/mL; 19% had compensated cirrhosis; and 32% were treatment-experienced.

Table 9 presents the SVR12 and other virologic outcomes in EPCLUSA treated patients in the ASTRAL-1 trial by HCV genotype. No patients in the placebo group achieved SVR12.

**Table 9 Study ASTRAL-1: SVR12 and Virologic Outcomes by HCV Genotype**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **EPCLUSA 12 Weeks (N=624)** | | | | | | | |
| **Total (all GTs) (N=624)** | **GT-1** | | | **GT-2 (N=104)** | **GT-4 (N=116)** | **GT-5 (N=35)** | **GT-6 (N=41)** |
| **GT-1a (N=210)** | **GT-1b (N=118)** | **Total (N=328)** |
| SVR12 | 99% (618/624) | 98% (206/210) | 99% (117/118) | 98% (323/328) | 100% (104/104) | 100% (116/116) | 97% (34/35) | 100% (41/41) |
| Outcome for Patients without SVR | | | | | | | | |
| On-Treatment Virologic Failure | 0/624 | 0/210 | 0/118 | 0/328 | 0/104 | 0/116 | 0/35 | 0/41 |
| Relapsea | <1% (2/623) | <1% (1/209) | 1% (1/118) | 1% (2/327) | 0/104 | 0/116 | 0/35 | 0/41 |
| Otherb | 1% (4/624) | 1% (3/210) | 0/118 | 1% (3/328) | 0/104 | 0/116 | 3% (1/35) | 0/41 |

a The denominator for relapse is the number of patients with HCV RNA <LLOQ at their last on-treatment assessment.

b Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Genotype 2 HCV-Infected Adults (ASTRAL-2)

ASTRAL-2 was a randomised, open-label trial that evaluated 12 weeks of treatment with EPCLUSA compared with 12 weeks of treatment with SOF+RBV in patients with genotype 2 HCV infection. Patients were randomised in a 1:1 ratio to treatment with EPCLUSA for 12 weeks or SOF+RBV for 12 weeks. Randomisation was stratified by the presence or absence of cirrhosis and prior treatment experience (treatment naïve vs treatment experienced).

Demographics and baseline characteristics were balanced across the two treatment groups. Of the 266 treated patients, the median age was 58 years (range: 23 to 81); 59% of the patients were male; 88% were White, 7% were Black; 33% had a baseline body mass index at least 30 kg/m2; 62% had non-CC IL28B alleles (CT or TT); 80% had baseline HCV RNA levels at least 800,000 IU/mL; 14% had compensated cirrhosis; and 15% were treatment-experienced.

Table 10 presents the SVR12 and other virologic outcomes from the ASTRAL-2 trial.

**Table 10 Study ASTRAL-2: SVR12 and Virologic Outcomes (HCV Genotype 2)**

|  |  |  |
| --- | --- | --- |
|  | **EPCLUSA 12 Weeks (N=134)** | **SOF+RBV 12 Weeks (N= 132)** |
| SVR12 | 99% (133/134) | 94% (124/132) |
| Outcome for Patients without SVR | | |
| On-Treatment Virologic Failure | 0/134 | 0/132 |
| Relapsea | 0/133 | 5% (6/132) |
| Otherb | 1% (1/134) | 2% (2/132) |

a The denominator for relapse is the number of patients with HCV RNA <LLOQ at their last on-treatment assessment.

b Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Treatment with EPCLUSA for 12 weeks demonstrated statistical superiority (p = 0.018) compared to treatment with SOF+RBV for 12 weeks (treatment difference +5.2%; 95% confidence interval: +0.2% to +10.3%).

Genotype 3 HCV-Infected Adults (ASTRAL-3)

ASTRAL-3 was a randomised, open-label trial that evaluated 12 weeks of treatment with EPCLUSA compared with 24 weeks of treatment with SOF+RBV in patients with genotype 3 HCV infection. Patients were randomised in a 1:1 ratio to treatment with EPCLUSA for 12 weeks or SOF+RBV for 24 weeks. Randomisation was stratified by the presence or absence of cirrhosis and prior treatment experience (treatment naïve vs treatment experienced).

Demographics and baseline characteristics were balanced across the treatment groups. Of the 552 treated patients, the median age was 52 years (range: 19 to 76); 62% of the patients were male; 89% were White, 9% were Asian; 20% had a baseline body mass index at least 30 kg/m2; 61% had non-CC IL28B alleles (CT or TT); 70% had baseline HCV RNA levels at least 800,000 IU/mL; 30% had compensated cirrhosis; and 26% were treatment-experienced.

Table 11 presents the SVR12 and other virologic outcomes for the ASTRAL-3 trial.

**Table 11 Study ASTRAL-3: SVR12 and Virologic Outcomes (HCV Genotype 3)**

|  |  |  |
| --- | --- | --- |
|  | **EPCLUSA 12 Weeks (N = 277)** | **SOF+RBV 24 Weeks (N = 275)** |
| SVR12 | 95% (264/277) | 80% (221/275) |
| Outcome for patients without SVR | | |
| On-Treatment Virologic Failure | 0/277 | <1% (1/275) |
| Relapsea | 4% (11/276) | 14% (38/272) |
| Otherb | 1% (2/277) | 5% (15/275) |

a The denominator for relapse is the number of patients with HCV RNA <LLOQ at their last on-treatment assessment.

b Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Treatment with EPCLUSA for 12 weeks demonstrated statistical superiority (p < 0.001) compared to treatment with SOF+RBV for 24 weeks (treatment difference +14.8%; 95% confidence interval: +9.6% to +20.0%).

SVR12 for selected subgroups are presented in Table 12.

**Table 12** **Study ASTRAL-3:** **SVR12 for Selected Subgroups (HCV Genotype 3)**

|  | **EPCLUSA 12 Weeks** | | **SOF+RBV 24 Weeksa** | |
| --- | --- | --- | --- | --- |
| **Treatment-Naïve (N=206)** | **Treatment-Experienced  (N=71)** | **Treatment-Naïve (N=201)** | **Treatment-Experienced (N=69)** |
| Without cirrhosis | 98% (160/163) | 91% (31/34) | 90% (141/156) | 71% (22/31) |
| With cirrhosis | 93% (40/43) | 89% (33/37) | 73% (33/45) | 58% (22/38) |

a Five patients with missing cirrhosis status in the SOF+RBV 24 Week group were excluded from this subgroup analysis.

**Clinical Studies in Patients with Decompensated Cirrhosis**

ASTRAL-4

ASTRAL-4 was a randomised, open-label trial in patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection and Child-Pugh B cirrhosis. Patients were randomised in a 1:1:1 ratio to treatment with EPCLUSA for 12 weeks, EPCLUSA+RBV for 12 weeks, or EPCLUSA for 24 weeks. Randomisation was stratified by HCV genotype (1, 2, 3, 4, 5, 6 and indeterminate).

Demographics and baseline characteristics were balanced across the treatment groups. Of the 267 treated patients, the median age was 59 years (range: 40 to 73); 70% of the patients were male; 90% were White, 6% were Black; 42% had a baseline body mass index at least 30 kg/m2; The proportions of patients with genotype 1, 2, 3, 4, or 6 HCV were 78%, 4%, 15%, 3%, and <1% (1 patient), respectively. No patients with genotype 5 HCV infection were enrolled. 76% had non-CC IL28B alleles (CT or TT); 56% had baseline HCV RNA levels at least 800,000 IU/mL; 55% were treatment-experienced; 90% and 95% of patients had CPT B cirrhosis and Model for End Stage Liver Disease (MELD) score ≤15 at baseline, respectively.

Table 13 presents the SVR12 for the ASTRAL-4 trial by HCV genotype.

**Table 13 Study ASTRAL-4: SVR12 by HCV Genotype**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **EPCLUSA  12 Weeks (N=90)** | **EPCLUSA+RBV  12 Weeks  (N=87)** | **EPCLUSA  24 Weeks  (N=90)** |
| Overall SVR12 | 83% (75/90) | 94% (82/87) | 86% (77/90) |
| Genotype 1 | 88% (60/68) | 96% (65/68) | 92% (65/71) |
| Genotype 1a | 88% (44/50) | 94% (51/54) | 93% (51/55) |
| Genotype 1b | 89% (16/18) | 100% (14/14) | 88% (14/16) |
| Genotype 3 | 50% (7/14) | 85% (11/13) | 50% (6/12) |
| Genotype 2, 4 and 6 | 100% (8/8)a | 100% (6/6)b | 86% (6/7)c |

a N=4 for genotype 2 and N=4 for genotype 4

b N=4 for genotype 2 and N=2 for genotype 4

c N=4 for genotype 2, N=2 for genotype 4, and N=1 for genotype 6.

Table 13 presents the virologic outcome for patients with genotype 1 or 3 HCV infection in the ASTRAL-4 trial.

No patients with genotype 2, 4, or 6 HCV infection experienced virologic failure.

**Table 14** **Study ASTRAL-4: Virologic Outcome for Patients with Genotype 1 and 3 HCV Infection**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **EPCLUSA 12 Weeks** | **EPCLUSA+RBV  12 Weeks** | **EPCLUSA 24 Weeks** |
| Virologic Failure (relapse and on-treatment failure) | | | |
| Genotype 1a | 7% (5/68) | 1% (1/68) | 4% (3/71) |
| Genotype 1a | 6% (3/50) | 2% (1/54) | 4% (2/55) |
| Genotype 1b | 11% (2/18) | 0% (0/14) | 6% (1/16) |
| Genotype 3 | 43% (6/14) | 15% (2b/13) | 42% (5c/12) |
| Otherd | 5% (4/82) | 2% (2/81) | 5% (4/83) |

1. No patients with genotype 1 HCV had on-treatment virologic failure.
2. One patients had on-treatment virologic failure; pharmacokinetic data from this patient was consistent with non-adherence.
3. One patients had on-treatment virologic failure.
4. Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Changes in MELD and CPT score from baseline to post-treatment Week 12 were analysed for patients who achieved SVR12 to assess the effect of SVR12 on hepatic function. Of the 82 patients treated with EPCLUSA+RBV for 12 weeks who achieved SVR12, 81 had MELD and CPT assessments at baseline and post-treatment week 12.

*Change in MELD score:* Among those who achieved SVR12 with 12 weeks treatment with EPCLUSA+RBV, 51% (41/81) and 15% (12/81) had an improvement or no change in MELD score from baseline to post-treatment week 12, respectively. Of the 10 patients whose MELD score was ≥ 15 at baseline, 40% (4/10) had a MELD score < 15 at post-treatment Week 12; Improvement in MELD score was due to improvements (decreases) in bilirubin.

*Change in CPT:* Among those who achieved SVR12 with 12 weeks treatment with EPCLUSA+RBV, 41% (33/81) and 49% (40/81) had an improvement or no change of CPT scores from baseline to post-treatment week 12, respectively; Improvement in CPT score was due to improvements in albumin (increases) and bilirubin (decreases).

Similar proportions of patients treated with EPCLUSA for 12 or 24 weeks had improvements in MELD and CPT scores compared with patients treated with EPCLUSA+RBV for 12 weeks.

**Clinical Studies in Patients with HCV/HIV-1 Co-infection – ASTRAL‑5**

ASTRAL-5 was a single arm, open-label study conducted in the US evaluating 12 weeks of treatment with EPCLUSA once daily in patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection who were co-infected with HIV-1. Patients were on a stable HIV-1 antiretroviral therapy that included emtricitabine/tenofovir disoproxil fumarate or abacavir/lamivudine administered with ritonavir boosted atazanavir, ritonavir boosted darunavir, ritonavir boosted lopinavir, rilpivirine, raltegravir or elvitegravir/cobicistat.

The study population included patients who were in general good health with exception of HCV and HIV. Exclusion criteria included HBV co-infection, HIV RNA > 50 copies/mL, CD4+ count < 100 cells/μL, opportunistic infection within 6 months of screening, active serious infection, decompensated liver disease, malignancy other than those cured by surgical resection and clinically significant illness other than HCV and HIV. The overall mean CD4+ count was 598 cells/μL (range: 183−1513 cells/μL), 57% of patients had CD4+ counts > 500 cells/μL, and 26% of patients had CD4+ counts ≥ 351 cells/μL and ≤ 500 cells/μL.

Of the 106 treated patients, the median age was 57 years (range: 25 to 72); 86% of the patients were male; 51% were White; 45% were Black; 22% had a baseline body mass index at least 30 kg/m2; the proportions of patients with genotype 1a, 1b, 2, 3, or 4 HCV infection were 62%; 11%; 10%; 11%, and 5% respectively; 77% had non-CC IL28B alleles (CT or TT); 74% had baseline HCV RNA levels of at least 800,000 IU/mL; 18% had compensated cirrhosis; and 29% were treatment experienced. No patients with genotype 5 or 6 HCV infection were enrolled.

Table 15 presents the SVR12 for the ASTRAL‑5 study by HCV genotype.

**Table 15: SVR12 in study ASTRAL‑5 by HCV genotype**

|  | **EPCLUSA 12 weeks**  **(N = 106)** | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Total**  **(all GTs)**  **(n = 106)** | **GT‑1** | | | **GT‑2**  **(n = 11)** | **GT‑3**  **(n = 12)** | **GT‑4**  **(n = 5)** |
| **GT‑1a**  **(n = 66)** | **GT‑1b**  **(n = 12)** | **Total**  **(n = 78)** |
| SVR12 | 95%a  (101/106) | 95%  (63/66) | 92%  (11/12) | 95%  (74/78) | 100%  (11/11) | 92%  (11/12) | 100%  (5/5) |
| Outcome for patients without SVR | | | | | | | |
| On-treatment virologic failure | 0/106 | 0/66 | 0/12 | 0/78 | 0/11 | 0/12 | 0/5 |
| Relapseb | 2%  (2/103) | 3%  (2/65) | 0/11 | 3%  (2/76) | 0/11 | 0/11 | 0/5 |
| Otherc | 3%  (3/106) | 2%  (1/66) | 8%  (1/12) | 3%  (2/78) | 0/11 | 8%  (1/12) | 0/5 |

GT = genotype

a. 95% confidence interval 89% to 99%

b. The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.

c. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.

No patient had HIV-1 rebound during the study, and CD4+ counts were stable during treatment.

**Clinical Trial in Patients with Renal Impairment**

Study GS-US-342-4062 was an open-label clinical trial that evaluated 12 weeks of treatment with EPCLUSA in 59 HCV-infected patients with ESRD requiring dialysis. The proportions of patients with genotype 1, 2, 3, 4, 6 or indeterminate HCV infection were 42%, 12%, 27%, 7%, 3%, and 9%, respectively. At baseline, 29% of patients had cirrhosis, 22% were treatment-experienced, 32% had received a kidney transplant, 92% were on haemodialysis, and 8% were on peritoneal dialysis; mean duration on dialysis was 7.3 years (range: 0 to 40 years). The overall SVR rate was 95% (56/59); of the 3 patients that did not achieve SVR12, 1 had completed EPCLUSA treatment and relapsed and 2 did not meet virologic failure criteria.

**Clinical Trial in Paediatrics**

The efficacy of 12 weeks of treatment with EPCLUSA in HCV-infected paediatric patients 12 years of age and older was evaluated in a Phase 2, open-label clinical trial in 102 patients (Cohort 1) with HCV infection.

EPCLUSA was evaluated in 102 patients 12 years to < 18 years of age with genotype 1, 2, 3, 4 or 6 HCV infection. A total of 80 patients (78%) were treatment-naïve and 22 patients (22%) were treatment-experienced. The mean weight was 61 kg (range 22 to 147 kg), median age was 15 years (range: 12 to 17); 51% of the patients were female; 73% were White, 9% were Black, and 11% were Asian; 14% were Hispanic/Latino; mean body mass index was 22.7 kg/m2 (range: 12.9 to 48.9 kg/m2); 58% had baseline HCV RNA levels ≥ 800,000 IU/mL; the proportions of patients with genotype 1, 2, 3, 4 or 6 HCV infection were 74%, 6%, 12%, 2%, and 6%, respectively; no patients had known cirrhosis. The majority of patients (89%) had been infected through vertical transmission.

The SVR rate was 95% overall (97/102), 93% (71/76) in patients with genotype 1 HCV infection, and 100% in patients with genotype 2 (6/6), genotype 3 (12/12), genotype 4 (2/2), and genotype 6 (6/6) HCV infection. One patient who discontinued treatment early relapsed at Post Treatment Week 4; the other four patients who did not achieve SVR12 did not meet virologic failure criteria (e.g., lost to follow-up).

## Pharmacokinetic properties

### Absorption

The pharmacokinetic properties of sofosbuvir, GS-331007 (the predominant circulating metabolite of sofosbuvir), and velpatasvir have been evaluated in healthy adult subjects and in patients with chronic hepatitis C. Following oral administration of EPCLUSA, sofosbuvir was absorbed quickly and the peak median plasma concentration was observed 0.5-1.0 hour post-dose. Median peak plasma concentration of GS-331007 was observed 3.0 hours post-dose. Velpatasvir median peak concentrations were observed 3.0 hours post-dose.

Based on the population pharmacokinetic analysis in HCV-infected patients, mean steady-state AUC0-24 for sofosbuvir (N=982), GS-331007 (N=1428), and velpatasvir (N=1425) were 1260, 13970, and 2970 ng•hr/mL, respectively. Steady-state Cmax for sofosbuvir, GS-331007, and velpatasvir were 566, 868, and 259 ng/mL, respectively. Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects and patients with HCV infection. Relative to healthy subjects (N=331), velpatasvir AUC0-24 and Cmax were 37% lower and 41% lower, respectively in HCV-infected patients.

Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 1200 mg. Velpatasvir AUC increases in a greater than proportional manner from 5 to 50 mg and in a less than proportional manner from 50 to 450 mg, indicating velpatasvir absorption is solubility limited. Sofosbuvir and velpatasvir are substrates for both P-gp and breast cancer resistance protein (BCRP)-mediated transport.

### Distribution

Sofosbuvir is approximately 61-65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 g/mL to 20 g/mL. Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of [14C]-sofosbuvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity was approximately 0.7.

Velpatasvir is >99.5% bound to human plasma proteins and binding is independent of drug concentration over the range of 0.09 g/mL to 1.8 g/mL. After a single 100 mg dose of [14C]- velpatasvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity ranged between 0.52 and 0.67.

### Metabolism

Sofosbuvir is extensively metabolised in the liver to form the pharmacologically active nucleoside analog triphosphate GS-461203. The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalysed by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway. Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity *in vitro*. After a single 400 mg oral dose of [14C]-sofosbuvir, GS-331007 accounted for approximately > 90% of total systemic exposure.

Velpatasvir is a substrate of CYP2B6, CYP2C8, and CYP3A4 with slow turnover. Following a single dose of 100 mg [14C]-velpatasvir, the majority (> 98%) of radioactivity in plasma was parent drug. Monohydroxylated and desmethylated velpatasvir were the metabolites identified in human plasma. Unchanged velpatasvir is the major species present in faeces.

### Excretion

Following a single 400 mg oral dose of [14C]-sofosbuvir, mean total recovery of the [14C]-radioactivity was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and expired air, respectively. The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir. These data indicate that renal clearance is the major elimination pathway for GS-331007. The median terminal half-lives of sofosbuvir and GS-331007 following administration of EPCLUSA were 0.5 and 25 hours, respectively.

Following a single 100 mg oral dose of [14C]-velpatasvir, mean total recovery of the [14C]-radioactivity was 95%, consisting of approximately 94% and 0.4% recovered from the faeces and urine, respectively. Unchanged velpatasvir was the major species in faeces accounting for a mean of 77% of the administered dose, followed by monohydroxylated velpatasvir (5.9%) and desmethylated velpatasvir (3.0%). These data indicate that biliary excretion of parent drug was the major route of elimination for velpatasvir. The median terminal half-life of velpatasvir following administration of EPCLUSA was approximately 15 hours.

**Effect of Food**

Relative to fasting conditions, the administration of a single dose of EPCLUSA with a moderate fat (~600 kcal, 30% fat) or high fat (~800 kcal, 50% fat) meal increased sofosbuvir AUC0-inf by 60% and 78%, respectively, but did not substantially affect the sofosbuvir Cmax. The moderate- or high-fat meal did not alter GS-331007 AUC0-inf, but resulted in a 25% and 37% decrease in Cmax, respectively. The moderate or high fat meal resulted in a 34% and 21% increase in velpatasvir AUC0-inf, respectively, and a 31% and 5% increase in velpatasvir Cmax, respectively. The response rates in Phase 3 trials were similar in HCV-infected patients who received EPCLUSA with food or without food. EPCLUSA can be administered without regard to food.

Special Populations

*Race and Gender*

No clinically relevant pharmacokinetic differences due to race have been identified for sofosbuvir, GS-331007, or velpatasvir.

No clinically relevant pharmacokinetic differences due to gender have been identified for sofosbuvir, GS-331007, or velpatasvir.

*Elderly Patients*

Population pharmacokinetic analysis in HCV-infected patients showed that within the age range (18 to 82 years) analysed, age did not have a clinically relevant effect on the exposure to sofosbuvir, GS-331007, or velpatasvir. Clinical studies of EPCLUSA included 156 patients aged 65 and over (12% of total number of patients in the Phase 3 clinical trials). The response rates observed for patients ≥ 65 years of age were similar to that of patients < 65 years of age, across treatment groups.

*Paediatric Patients*

Exposure of sofosbuvir, GS-331007 and velpatasvir in 102 paediatric patients ≥ 12 years of age who received EPCLUSA in Study GS-US-342-1143 were similar to those observed in adult patients following administration of EPCLUSA. Population pharmacokinetics-based simulations indicated exposures of sofosbuvir, GS-331007, and velpatasvir in paediatric patients weighing ≥ 30 kg receiving oral once daily doses of sofosbuvir/velpatasvir 400/100 mg were similar to those observed in adults.

*Patients with Impaired Renal Function*

A summary of the effect of varying degrees of renal impairment (RI) on the exposures of the components of EPCLUSA compared to subjects with normal renal function, as described in the text below, are provided in Table 16

**Table 16: Effect of Varying Degrees of Renal Impairment on Exposures (AUC) of Sofosbuvir, GS-331007, and Velpatasvir Compared to Subjects with Normal Renal Function**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HCV-Negative Subjects** | | | | | **HCV-Infected Subjects** | |
| Mild RI  (eGFR ≥50 and <80 mL/min/1.73m2) | Moderate RI  (eGFR ≥30 and <50 mL/min/1.73m2) | Severe RI  (eGFR <30 mL/min/1.73m2) | ESRD Requiring Dialysis | | Severe RI  (eGFR <30 mL/min/1.73m2) | ESRD Requiring Dialysis |
| Dosed 1 hr Before Dialysis | Dosed 1 hr After Dialysis |
| Sofosbuvir | 1.6-fold↑ | 2.1-fold↑ | 2.7-fold↑ | 1.3-fold↑ | 1.6-fold↑ | ~2-fold↑ | 1.8-fold↑ |
| GS‑331007 | 1.6-fold↑ | 1.9-fold↑ | 5.5-fold↑ | ≥10-fold↑ | ≥20-fold↑ | ~7-fold↑ | 18-fold↑ |
| Velpatasvir | - | - | 1.5-fold↑ | - | - | - | 1.4-fold↑ |

The pharmacokinetics of sofosbuvir was studied in HCV negative adult patients with mild (eGFR ≥ 50 and < 80 mL/min/1.73 m2), moderate (eGFR ≥ 30 and < 50 mL/min/1.73 m2), severe renal impairment (eGFR < 30 mL/min/1.73 m2) and patients with ESRD requiring haemodialysis following a single 400 mg dose of sofosbuvir, relative to patients with normal renal function (eGFR > 80 mL/min/1.73 m2). GS‑331007 is efficiently removed by haemodialysis with an extraction coefficient of approximately 53%. Following a single 400 mg dose of sofosbuvir, a 4 hour haemodialysis removed 18% of administered dose.

In HCV-infected patients with severe renal impairment treated with sofosbuvir 200 mg with ribavirin (n=10) or sofosbuvir 400 mg with ribavirin (n=10) for 24 weeks or ledipasvir/sofosbuvir 90/400 mg (n=18) for 12 weeks, the pharmacokinetics of sofosbuvir and GS-331007 were consistent with that observed in HCV negative adult patients with severe renal impairment.

The pharmacokinetics of velpatasvir was studied with a single dose of 100 mg velpatasvir in HCV negative patients with severe renal impairment (eGFR < 30 mL/min by Cockcroft-Gault).

The pharmacokinetics of sofosbuvir, GS-331007, and velpatasvir were studied in HCV-infected patients with ESRD requiring dialysis treated with EPCLUSA (n=59) for 12 weeks, and compared to patients without renal impairment in the sofosbuvir/velpatasvir Phase 2/3 trials.

*Patients with Hepatic Impairment*

The pharmacokinetics of sofosbuvir were studied following 7-day dosing of 400 mg sofosbuvir in HCV-infected patients with moderate and severe hepatic impairment (Child Pugh Class B and C). Relative to patients with normal hepatic function, the sofosbuvir AUC0-24 was 126% and 143% higher in moderate and severe hepatic impairment, while the GS-331007 AUC0-24 was 18% and 9% higher, respectively. Population pharmacokinetics analysis in HCV-infected patients indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure of sofosbuvir and GS-331007. No dose adjustment of sofosbuvir is recommended for patients with mild, moderate, and severe hepatic impairment.

The pharmacokinetics of velpatasvir were studied with a single dose of 100 mg velpatasvir in HCV negative patients with moderate and severe hepatic impairment (Child Pugh Class B and C). Velpatasvir plasma exposure (AUCinf) was similar in patients with moderate hepatic impairment, severe hepatic impairment, and control patients with normal hepatic function. Population pharmacokinetics analysis in HCV-infected patients indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure of velpatasvir. No dose adjustment of velpatasvir is required for patients with mild, moderate, or severe hepatic impairment.

Assessment of Drug Interactions

After oral administration of EPCLUSA, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic extraction. Hydrolytic prodrug cleavage and sequential phosphorylation steps results in formation of the pharmacologically active uridine nucleoside analog triphosphate. Dephosphorylation of nucleotide metabolites results in conversion to the predominant circulating metabolite GS-331007 that accounts for approximately 85% of total systemic exposure. In clinical pharmacology studies, both sofosbuvir and GS-331007 were monitored for purposes of pharmacokinetic analyses.

Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP, while GS-331007 is not. Velpatasvir is poorly transported by OATP1B1 and OATP1B3. *In vitro*, slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed.

Sofosbuvir and GS-331007 are not inhibitors of drug transporters P-gp, BCRP, OATP1B1, OATP1B3, and OCT1, and GS-331007 is not an inhibitor of OAT1, OAT3, OCT2, and MATE1. Sofosbuvir and GS-331007 are not inhibitors or inducers of CYP or UGT1A1 enzymes.

Velpatasvir is an inhibitor of drug transporter P-gp, BCRP, OATP1B1, and OATP1B3, and its involvement in drug interactions with these transporters is primarily limited to the process of absorption. At clinically relevant concentration, velpatasvir is not an inhibitor of hepatic transporters OATP1A2 or OCT1, renal transporters OCT2, OAT1, OAT3 or MATE1, or CYP or UGT1A1 enzymes.

The effects of coadministered drugs on the exposure of sofosbuvir, GS-331007, and velpatasvir are shown in Table 17. The effects of sofosbuvir, velpatasvir or EPCLUSA on the exposure of coadministered drugs are shown in Table 18.

**Table 17 Drug Interactions: Changes in Pharmacokinetic Parameters for Sofosbuvir, its Predominant Circulating Metabolite GS-331007, and Velpatasvir in the Presence of the Coadministered Druga**

| **Co- administered Drug** | **Dose of Co- administered Drug (mg)** | **Velpatasvir Dose (mg)** | **Sofosbuvir Dose (mg)** | **N** | **Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK With/Without Coadministered Drug No Effect=1.00** | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Cmax** | **AUC** | **Cmin** |
| Atazanavir/ ritonavir + emtricitabine/ tenofovir DF | 300/100 +  200/300 once daily | 100 once daily | 400 once daily | 24 | sofosbuvir | 1.12 (0.97, 1.29) | 1.22 (1.12, 1.33) | NA |
| GS-331007 | 1.21 (1.12, 1.29) | 1.32 (1.27, 1.36) | 1.42 (1.37, 1.49) |
| velpatasvir | 1.55 (1.41, 1.71) | 2.42 (2.23, 2.64) | 4.01 (3.57, 4.50) |
| Carbamazepine | 300 twice daily | ND | 400 single dose | 24 | sofosbuvir | 0.52  (0.43, 0.62) | 0.52  (0.46, 0.59) | NA |
| GS-331007 | 1.04 (0.97, 1.11) | 0.99  (0.94, 1.04) | NA |
| Cyclosporine | 600 single dose | ND | 400 single dose | 19 | sofosbuvir | 2.54 (1.87, 3.45) | 4.53 (3.26, 6.30) | NA |
| GS-331007 | 0.60 (0.53, 0.69) | 1.04 (0.90, 1.20) | NA |
| 100 single dose | ND | 12 | velpatasvir | 1.56 (1.22, 2.01) | 2.03 (1.51, 2.71) | NA |
| Darunavir/ ritonavir + emtricitabine/ tenofovir DF | 800/100 +  200/300 once daily | 100 once daily | 400 once daily | 29 | sofosbuvir | 0.62 (0.54, 0.71) | 0.72 (0.66, 0.80) | NA |
| GS-331007 | 1.04 (0.99, 1.08) | 1.13 (1.08, 1.18) | 1.13 (1.06, 1.19) |
| velpatasvir | 0.76 (0.65, 0.89) | 0.84 (0.72, 0.98) | 1.01 (0.87, 1.18) |
| Dolutegravir | 50 once daily | 100 once daily | 400 once daily | 24 | sofosbuvir | 0.88 (0.80, 0.98) | 0.92 (0.85, 0.99) | NA |
| GS-331007 | 1.01 (0.93, 1.10) | 0.99 (0.97, 1.01) | 0.99 (0.97, 1.01) |
| velpatasvir | 0.94 (0.86, 1.02) | 0.91 (0.84, 0.98) | 0.88 (0.82, 0.94) |
| Efavirenz/ emtricitabine/ tenofovir DFb | 600/200/300 once daily | 100 once daily | 400 once daily | 14 | sofosbuvir | 1.38 (1.14, 1.67) | 0.97 (0.83, 1.14) | NA |
| GS-331007 | 0.86 (0.80, 0.93) | 0.90 (0.85, 0.96) | 1.01 (0.95, 1.07) |
| velpatasvir | 0.53 (0.43, 0.64) | 0.47 (0.39, 0.57) | 0.43 (0.36, 0.52) |
| Elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamidec | 150/150/200/  10 once daily | 100 once daily | 400 once daily | 24 | sofosbuvir | 1.23 (1.07, 1.42) | 1.37 (1.24, 1.52) | NA |
| GS-331007 | 1.29 (1.25, 1.33) | 1.48 (1.43, 1.53) | 1.58 (1.52, 1.65) |
| velpatasvir | 1.30 (1.17, 1.45) | 1.50 (1.35, 1.66) | 1.60 (1.44, 1.78) |
| Elvitegravir/ cobicistat/ emtricitabine/ tenofovir DFd | 150/150/200/  300 once daily | 100 once daily | 400 once daily | 24 | sofosbuvir | 1.01 (0.85, 1.19) | 1.24 (1.13, 1.37) | NA |
| GS-331007 | 1.13 (1.07, 1.18) | 1.35 (1.30, 1.40) | 1.45 (1.38, 1.52) |
| velpatasvir | 1.05 (0.93, 1.19) | 1.19 (1.07, 1.34) | 1.37 (1.22, 1.54) |
| Emtricitabine/ rilpivirine/ tenofovir DFe | 200/25/300 once daily | 100 once daily | 400 once daily | 24 | sofosbuvir | 1.09 (0.95, 1.25) | 1.16 (1.09, 1.24) | NA |
| GS-331007 | 0.96 (0.90, 1.01) | 1.04 (1.00, 1.07) | 1.12 (1.07, 1.17) |
| velpatasvir | 0.96 (0.85, 1.10) | 0.99 (0.88, 1.11) | 1.02 (0.91, 1.15) |
| Famotidine | 40 single dose simultaneously with EPCLUSA | 100 single dose | 400 single dose | 60 | sofosbuvir | 0.92 (0.82, 1.05) | 0.82 (0.74, 0.91) | NA |
| GS-331007 | 0.84 (0.78, 0.89) | 0.94 (0.91, 0.98) | NA |
| velpatasvir | 0.80 (0.70, 0.91) | 0.81 (0.71, 0.91) | NA |
| 40 single dose  12 hours prior to EPCLUSA | 60 | sofosbuvir | 0.77 (0.68, 0.87) | 0.80 (0.73, 0.88) | NA |
| GS-331007 | 1.20 (1.13, 1.28) | 1.04 (1.01, 1.08) | NA |
| velpatasvir | 0.87 (0.76, 1.00) | 0.85 (0.74, 0.97) | NA |
| Ketoconazole | 200 twice daily | 100 single dose | ND | 12 | velpatasvir | 1.29 (1.02, 1.64) | 1.71 (1.35, 2.18) | NA |
| Lopinavir/ ritonavir + emtricitabine/ tenofovir DF | 4 x 200/50 +  200/300 once daily | 100 once daily | 400 once daily | 24 | sofosbuvir | 0.59 (0.49, 0.71) | 0.71 (0.64, 0.78) | NA |
| GS-331007 | 1.01 (0.98, 1.05) | 1.15 (1.09, 1.21) | 1.15 (1.07, 1.25) |
| velpatasvir | 0.70 (0.59, 0.83) | 1.02 (0.89, 1.17) | 1.63 (1.43, 1.85) |
| Methadone | 30 to 130 daily | ND | 400 once daily | 14 | sofosbuvir | 0.95 (0.68, 1.33) | 1.30 (1.00, 1.69) | NA |
| GS-331007 | 0.73 (0.65, 0.83) | 1.04 (0.89, 1.22) | NA |
| Omeprazole | 20 once daily simultaneously with EPCLUSA | 100 single dose fasted | 400 single dose fasted | 60 | sofosbuvir | 0.66 (0.55, 0.78) | 0.71 (0.60, 0.83) | NA |
| GS-331007 | 1.18 (1.10, 1.26) | 1.00 (0.95, 1.05) | NA |
| velpatasvir | 0.63 (0.50, 0.78) | 0.64 (0.52, 0.79) | NA |
| 20 once daily  12 hours prior to EPCLUSA | 100 single dose fasted | 400 single dose fasted | 60 | sofosbuvir | 0.55 (0.47, 0.64) | 0.56 (0.49, 0.65) | NA |
| GS-331007 | 1.26 (1.18, 1.34) | 0.97 (0.94, 1.01) | NA |
| velpatasvir | 0.43 (0.35, 0.54) | 0.45 (0.37, 0.55) | NA |
| 20 once daily  2 hours prior to  EPCLUSA | 100 single dose fed | 400 single dose fed | 40 | sofosbuvir | 0.84 (0.68, 1.03) | 1.08 (0.94, 1.25) | NA |
| GS-331007 | 0.94 (0.88, 1.02) | 0.99 (0.96, 1.03) | NA |
| velpatasvir | 0.52 (0.43, 0.64) | 0.62 (0.51, 0.75) | NA |
| 20 once daily  4 hours after  EPCLUSA | 100 single dose fed | 400 single dose fed | 38 | sofosbuvir | 0.79 (0.68, 0.92) | 1.05 (0.94, 1.16) | NA |
| GS-331007 | 0.91 (0.85, 0.98) | 0.99 (0.95, 1.02) | NA |
| velpatasvir | 0.67 (0.58, 0.78) | 0.74 (0.63, 0.86) | NA |
| 40 once daily  4 hours after EPCLUSA | 100 single dose fed | 400 single dose fed | 40 | sofosbuvir | 0.70 (0.57, 0.87) | 0.91 (0.76, 1.08) | NA |
| GS-331007 | 1.01 (0.96, 1.07) | 0.99 (0.94, 1.03) | NA |
| velpatasvir | 0.44 (0.34, 0.57) | 0.47 (0.37, 0.60) | NA |
| Raltegravir + emtricitabine/ tenofovir DF | 400 twice daily + 200/300 once daily | 100 once daily | 400 once daily | 30 | sofosbuvir | 1.09 (0.97, 1.23) | 1.16 (1.07, 1.25) | NA |
| GS-331007 | 0.95 (0.91, 0.98) | 1.03 (1.00, 1.06) | 1.08 (1.04, 1.13) |
| velpatasvir | 0.97 (0.87, 1.08) | 0.98 (0.88, 1.10) | 0.97 (0.87, 1.07) |
| Rifabutin | 300 once daily | ND | 400 single dose | 20 | sofosbuvir | 0.64 (0.53, 0.77) | 0.76 (0.63, 0.91) | NA |
| GS-331007 | 1.15 (1.03, 1.27) | 1.03 (0.95, 1.12) | NA |
| Rifampin | 600 once daily | ND | 400 single dose | 17 | sofosbuvir | 0.23 (0.19, 0.29) | 0.28 (0.24, 0.32) | NA |
| GS-331007 | 1.23 (1.14, 1.34) | 0.95 (0.88, 1.03) | NA |
| 100 single dose | ND | 12 | velpatasvir | 0.29 (0.23, 0.37) | 0.18 (0.15, 0.22) | NA |
| 600 single dose | 100 single dose | ND | 12 | velpatasvir | 1.28 (1.05, 1.56) | 1.46 (1.17, 1.83) | NA |
| Tacrolimus | 5 single dose | ND | 400 single dose | 16 | sofosbuvir | 0.97 (0.65, 1.43) | 1.13 (0.81, 1.57) | NA |
| GS-331007 | 0.97 (0.83, 1.14) | 1.00 (0.87, 1.13) | NA |

NA = not available/not applicable, ND = not dosed.

a. All interaction studies conducted in healthy volunteers.

b. Administered as Atripla (efavirenz, emtricitabine and tenofovir DF fixed-dose combination).

c. Administered as Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide fixed-dose combination).

d. Administered as Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir DF fixed-dose combination).

e. Administered as Eviplera (emtricitabine, rilpivirine and tenofovir DF fixed-dose combination).

**Table 18 Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Sofosbuvir, Velpatasvir, or EPCLUSAa**

| **Co-administered Drug** | **Dose of Co- administered  Drug (mg)** | | | **Velpatasvir Dose (mg)** | | **Sofosbuvir Dose (mg)** | **N** | **Mean Ratio (90% CI) of Coadministered Drug PK With/Without Sofosbuvir, Velpatasvir or EPCLUSA  No Effect=1.00** | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cmax** | **AUC** | **Cmin** | |
| Atazanavir/ ritonavir  + emtricitabine/ tenofovir DFb | atazanavir 300 once daily | | | 100 once daily | | 400 once daily | 24 | 1.09 (1.00, 1.19) | 1.20 (1.10, 1.31) | 1.39 (1.20, 1.61) | |
| ritonavir 100 once daily | | | 0.89 (0.82, 0.97) | 0.97 (0.89, 1.05) | 1.29 (1.15, 1.44) | |
| emtricitabine 200 once daily | | | 1.01 (0.96, 1.06) | 1.02 (0.99, 1.04) | 1.06 (1.02, 1.11) | |
| tenofovir DF 300 once daily | | | 1.55 (1.43, 1.68) | 1.30 (1.24, 1.36) | 1.39 (1.31, 1.48) | |
| Atorvastatin | 40 single dose | | | 100 once daily | | 400 once daily | 26 | 1.68  (1.49,1.89) | 1.54  (1.45, 1.64) | NA | |
| Cyclosporine | 600 single dose | | | 100 single dose | | ND | 12 | 0.92 (0.82, 1.02) | 0.88 (0.78, 1.00) | NA | |
| ND | | 400 single dose | 19 | 1.06 (0.94, 1.18) | 0.98 (0.85, 1.14) | NA | |
| Darunavir/ritonavir + emtricitabine/ tenofovir DFc | darunavir 800 once daily | | | 100 once daily | | 400 once daily | 29 | 0.90 (0.86, 0.95) | 0.92 (0.87, 0.98) | 0.87 (0.79, 0.95) | |
| ritonavir 100 once daily | | | 1.07 (0.97, 1.17) | 1.12 (1.05, 1.19) | 1.09 (1.02, 1.15) | |
| emtricitabine 200 once daily | | | 1.05 (1.01, 1.08) | 1.05 (1.02, 1.08) | 1.04 (0.98, 1.09) | |
| tenofovir DF 300 once daily | | | 1.55 (1.45, 1.66) | 1.39 (1.33, 1.44) | 1.52 (1.45, 1.59) | |
| Digoxin | 0.25 single dose | | | 100 | | ND | 21 | 1.88 (1.71, 2.08) | 1.34 (1.13, 1.60) | NA | |
| Dolutegravir | 50 once daily | | | 100 once daily | | 400 once daily | 24 | 1.06 (1.01, 1.11) | 1.06 (1.01, 1.13) | 1.04 (0.98, 1.10) | |
| Efavirenz/ emtricitabine/ tenofovir DFd | efavirenz 600 once daily | | | 100 once daily | | 400 once daily | 15 | 0.81 (0.74, 0.89) | 0.85 (0.80, 0.91) | 0.90 (0.85, 0.95) | |
| emtricitabine 200 once daily | | | 1.07 (0.98, 1.18) | 1.07 (1.00, 1.14) | 1.10 (0.97, 1.25) | |
| tenofovir DF 300 once daily | | | 1.77 (1.53, 2.04) | 1.81 (1.68, 1.94) | 2.21 (2.00, 2.43) | |
| Elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamidee | elvitegravir 150 once daily | | | 100 once daily | | 400 once daily | 24 | 0.87 (0.80, 0.94) | 0.94 (0.88, 1.00) | 1.08 (0.97, 1.20) | |
| cobicistat 150 once daily | | | 1.16 (1.09, 1.23) | 1.30 (1.23, 1.38) | 2.03 (1.67, 2.48) | |
| emtricitabine 200 once daily | | | 1.02 (0.97, 1.06) | 1.01 (0.98, 1.04) | 1.02 (0.97, 1.07) | |
| tenofovir alafenamide 10 once daily | | | 0.80 (0.68, 0.94) | 0.87 (0.81, 0.94) | NA | |
| Elvitegravir/ cobicistat/ emtricitabine/ tenofovir DFf | | elvitegravir 150 once daily | 100 once daily | | 400 once daily | | 24 | 0.93 (0.86, 1.00) | 0.93 (0.87, 0.99) | 0.97 (0.91, 1.04) |
| cobicistat 150 once daily | 1.11 (1.06, 1.17) | 1.23 (1.17, 1.29) | 1.71 (1.54, 1.90) |
| emtricitabine 200 once daily | 1.02 (0.97, 1.08) | 1.01 (0.98, 1.04) | 1.06 (1.01, 1.11) |
| tenofovir DF 300 once daily | 1.36 (1.25, 1.47) | 1.35 (1.29, 1.42) | 1.45 (1.39, 1.51) |
| Emtricitabine/ rilpivirine/ tenofovir DFg | | emtricitabine once 200 daily | 100 once daily | | 400 once daily | | 24 | 0.95 (0.90, 1.00) | 0.99 (0.97, 1.02) | 1.05 (0.99, 1.11) |
| rilpivirine 25 once daily | 0.93 (0.88, 0.98) | 0.95 (0.90, 1.00) | 0.96 (0.90, 1.03) |
| tenofovir DF 300 once daily | 1.44 (1.33, 1.55) | 1.40 (1.34, 1.46) | 1.84 (1.76, 1.92) |
| Lopinavir/ ritonavir +  emtricitabine/ tenofovir DF | | lopinavir 200 x 4 once daily | 100 once daily | | 400 once daily | | 24 | 0.97 (0.92, 1.02) | 1.00 (0.93, 1.06) | 1.11 (0.96, 1.30) |
| ritonavir 50 x 4 once daily | 0.94 (0.83, 1.07) | 0.97 (0.89, 1.05) | 1.07 (0.95, 1.20) |
| emtricitabine 200 once daily | 1.02 (0.93, 1.12) | 1.00 (0.94, 1.06) | 0.97 (0.91, 1.04) |
| tenofovir DF 300 once daily | 1.42 (1.27, 1.57) | 1.22 (1.14, 1.31) | 1.28 (1.20, 1.37) |
| R-Methadone | | 30 to 130 daily | ND | | 400 once daily | | 14 | 0.99 (0.85, 1.16) | 1.01 (0.85, 1.21) | 0.94 (0.77, 1.14) |
| S-Methadone | | 0.95 (0.79, 1.13) | 0.95 (0.77, 1.17) | 0.95 (0.74, 1.22) |
| Norelgestromin | | norgestimate  0.180/0.215/0.250/ ethinyl estradiol 0.025 once daily | 100 once daily | | ND | | 13 | 0.97 (0.88, 1.07) | 0.90 (0.82, 0.98) | 0.92 (0.83, 1.03) |
| ND | | 400 once daily | | 15 | 1.07 (0.94, 1.22) | 1.06 (0.92, 1.21) | 1.07 (0.89, 1.28) |
| Norgestrel | | 100 once daily | | ND | | 13 | 0.96 (0.78, 1.19) | 0.91 (0.73, 1.15) | 0.92 (0.73, 1.18) |
| ND | | 400 once daily | | 15 | 1.18 (0.99, 1.41) | 1.19 (0.98, 1.45) | 1.23 (1.00, 1.51) |
| Ethinyl estradiol | | 100 once daily | | ND | | 12 | 1.39 (1.17, 1.66) | 1.04 (0.87, 1.24) | 0.83 (0.65, 1.06) |
| ND | | 400 once daily | | 15 | 1.15 (0.97, 1.36) | 1.09 (0.94, 1.26) | 0.99 (0.80, 1.23) |
| Pravastatin | | 40 single dose | 100 once daily | | | ND | 18 | 1.28 (1.08, 1.52) | 1.35 (1.18, 1.54) | NA | |
| Rosuvastatin | | 10 single dose | 100 once daily | | | ND | 18 | 2.61 (2.32, 2.92) | 2.69 (2.46, 2.94) | NA | |
| Raltegravir + emtricitabine/ tenofovir DF | | emtricitabine 200 once daily | 100 once daily | | | 400 once daily | 30 | 1.08 (1.04, 1.12) | 1.05 (1.03, 1.07) | 1.02 (0.97, 1.08) | |
| tenofovir DF 300 once daily | 1.46 (1.39, 1.54) | 1.40 (1.34, 1.45) | 1.70 (1.61, 1.79) | |
| raltegravir 400 twice daily | 1.03 (0.74, 1.43) | 0.97 (0.73, 1.28) | 0.79 (0.42, 1.48) | |
| Tacrolimus | | 5 single dose | ND | | | 400 single dose | 16 | 0.73 (0.59, 0.90) | 1.09 (0.84, 1.40) | NA | |

NA = not available/not applicable, ND = not dosed.

a. All interaction studies conducted in healthy volunteers.

b. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/tenofovir DF.

c. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/tenofovir DF.

d. Administered as Atripla (efavirenz, emtricitabine and tenofovir DF fixed-dose combination).

e. Administered as Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide fixed-dose combination).

f. Administered as Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir DF fixed-dose combination).

g. Administered as Eviplera (emtricitabine, rilpivirine and tenofovir DF fixed-dose combination).

## Preclinical safety data

**Genotoxicity**

Sofosbuvir was not genotoxic in a battery of *in vitro* or *in vivo* assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and *in vivo* mouse micronucleus assays.

Velapatasvir was not genotoxic in a battery of *in vitro* or *in vivo* assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and *in vivo* rat micronucleus assays.

**Carcinogenicity**

Carcinogenicity studies in mice and rats do not indicate any carcinogenicity potential of sofosbuvir administered at doses up to 200 mg/kg/day in male mice and 600 mg/kg/day in female mice, and 750 mg/kg/day in rats. Exposure to GS-331007 in these studies in mice was up to 3 x (male) and 15 x (female), and in rats up to 7 x (male) and 9 x (female) higher than the clinical exposure at 400 mg sofosbuvir.

Velpatasvir was not carcinogenic in a 26-week transgenic mouse study and a 2-year rat carcinogenicity study at up to 1000 mg/kg/day and 200 mg/kg/day, respectively, which resulted in systemic exposures approximately 74-times and 6-times, respectively, the human exposure based on AUC.

# PHARMACEUTICAL PARTICULARS

## List of excipients

EPCLUSA tablets contain the following ingredients as excipients:

Tablet core: copovidone, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.

Film coating: polyvinyl alcohol, macrogol 3350, titanium dioxide, talc-purified, and iron oxide red.

## Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

## Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

## Special precautions for storage

EPCLUSA should be stored below 30 °C.

## Nature and contents of container

EPCLUSA is supplied in high density polyethylene (HDPE) bottles containing 28 tablets and is closed with a child resistant closure.

## Special precautions for disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

## Physicochemical properties

### Chemical structure


Sofosbuvir is a nucleotide inhibitor of HCV NS5B RNA-dependent RNA polymerase and velpatasvir is an HCV NS5A inhibitor.

The chemical name of sofosbuvir is (*S*)-Isopropyl 2-((*S*)-(((2*R*,3*R*,4*R*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate. It has a molecular formula of C22H29FN3O9P and a molecular weight of 529.45. It has the following structural formula:



Sofosbuvir is a white to off-white powder with a solubility of ≥ 2 mg/mL across the pH range of 2-7.7 at 37 °C. The partition coefficient (log P) for sofosbuvir is 1.62 and the pKa is 9.3.

The chemical name of velpatasvir is Methyl {(1*R*)-2-[(2*S*,4*S*)-2-(5-{2-[(2*S*,5*S*)-1-{(2*S*)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-*d*]imidazol-9-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate. It has a molecular formula of C49H54N8O8 and a molecular weight of 883.0. It has the following structural formula:



Velpatasvir is practically insoluble (less than 0.1 mg/mL) above pH 5, slightly soluble (3.6 mg/mL) at pH 2, and soluble (greater than 36 mg/mL) at pH 1.2.

### CAS number

Sofosbuvir CAS registry number: 1190307-88-0

Velpatasvir CAS registry number: 1377049-84-7

# Medicine schedule (Poisons Standard)

S4

# Sponsor

Gilead Sciences Pty Ltd

Level 6, 417 St Kilda Road

Melbourne, Victoria 3004

# Date of first approval

19 December 2016

# Date of revision

13 April 2021

## Summary table of changes

|  |  |
| --- | --- |
| Section Changed | Summary of new information |
| 4.1, 4.2, 4.8, 5.1, 5.2 | Extension of Indication to include paediatric patients aged 12 years of age and older based on efficacy and safety data from Study GS-US-342-1143. |
| 4.2, 4.8, 5.1, 5.2 | Update to include efficacy and safety data from Study GS-US-342-4062, HCV-infected adult patients with severe renal impairment or end-stage renal disease (ESRD). |
| 4.4,4.5, 5.2 | Inducers Reclassification and update to include data from a clinical pharmacology Study GS-US-334-2130 that evaluated the effect of rifabutin or carbamazepine administration on SOF pharmacokinetics and the effect of rifampin, rifabutin or carbamazepine administration on the activity of drug transporters and cytochrome P450 enzymes support the removal of oxcarbazepine as a potentially significant drug interaction. |
| 5.3 | Update to include results from nonclinical Study TX-281-2030 (A 2-year oral carcinogenicity study of velpatasvir in Sprague-Dawley Rats) |

Epclusa, Eviplera, Genvoya, Harvoni, Stribild, Truvada and Viread are trademarks of Gilead Sciences, Inc., or its related companies. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. All other trademarks referenced herein are the property of their respective owners